Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children</title><author><name sortKey="Escamilla Nu Ez, Maria Consuelo" sort="Escamilla Nu Ez, Maria Consuelo" uniqKey="Escamilla Nu Ez M" first="María Consuelo" last="Escamilla-Nu Ez">María Consuelo Escamilla-Nu Ez</name></author><author><name sortKey="Barraza Villarreal, Albino" sort="Barraza Villarreal, Albino" uniqKey="Barraza Villarreal A" first="Albino" last="Barraza-Villarreal">Albino Barraza-Villarreal</name></author><author><name sortKey="Hernandez Cadena, Leticia" sort="Hernandez Cadena, Leticia" uniqKey="Hernandez Cadena L" first="Leticia" last="Hernández-Cadena">Leticia Hernández-Cadena</name></author><author><name sortKey="Navarro Olivos, Efrain" sort="Navarro Olivos, Efrain" uniqKey="Navarro Olivos E" first="Efraín" last="Navarro-Olivos">Efraín Navarro-Olivos</name></author><author><name sortKey="Sly, Peter D" sort="Sly, Peter D" uniqKey="Sly P" first="Peter D." last="Sly">Peter D. Sly</name></author><author><name sortKey="Romieu, Isabelle" sort="Romieu, Isabelle" uniqKey="Romieu I" first="Isabelle" last="Romieu">Isabelle Romieu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24626819</idno><idno type="pmc">4122276</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122276</idno><idno type="RBID">PMC:4122276</idno><idno type="doi">10.1378/chest.13-1432</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001828</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001828</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children</title><author><name sortKey="Escamilla Nu Ez, Maria Consuelo" sort="Escamilla Nu Ez, Maria Consuelo" uniqKey="Escamilla Nu Ez M" first="María Consuelo" last="Escamilla-Nu Ez">María Consuelo Escamilla-Nu Ez</name></author><author><name sortKey="Barraza Villarreal, Albino" sort="Barraza Villarreal, Albino" uniqKey="Barraza Villarreal A" first="Albino" last="Barraza-Villarreal">Albino Barraza-Villarreal</name></author><author><name sortKey="Hernandez Cadena, Leticia" sort="Hernandez Cadena, Leticia" uniqKey="Hernandez Cadena L" first="Leticia" last="Hernández-Cadena">Leticia Hernández-Cadena</name></author><author><name sortKey="Navarro Olivos, Efrain" sort="Navarro Olivos, Efrain" uniqKey="Navarro Olivos E" first="Efraín" last="Navarro-Olivos">Efraín Navarro-Olivos</name></author><author><name sortKey="Sly, Peter D" sort="Sly, Peter D" uniqKey="Sly P" first="Peter D." last="Sly">Peter D. Sly</name></author><author><name sortKey="Romieu, Isabelle" sort="Romieu, Isabelle" uniqKey="Romieu I" first="Isabelle" last="Romieu">Isabelle Romieu</name></author></analytic><series><title level="j">Chest</title><idno type="ISSN">0012-3692</idno><idno type="eISSN">1931-3543</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>BACKGROUND:</title><p>Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.</p></sec><sec><title>METHODS:</title><p>We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18-35 years of age) to receive 400 mg/d of algal docosahexaenoic acid (DHA) or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months were available for 869 mother-child pairs. Questionnaires were administered, and maternal blood samples were obtained at baseline. Maternal atopy was based on specific IgE levels. During follow-up, information on infants’ respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12, and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.</p></sec><sec><title>RESULTS:</title><p>Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion (0.78; 95% CI, 0.60-1.02) and fever with phlegm and nasal discharge or nasal congestion (0.53; 95% CI, 0.29-0.99), adjusting for potential confounders.</p></sec><sec><title>CONCLUSIONS:</title><p>Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopy.</p></sec><sec><title>TRIAL REGISTRY:</title><p><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link>; No.: NCT00646360; URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link></p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Chest</journal-id><journal-id journal-id-type="iso-abbrev">Chest</journal-id><journal-id journal-id-type="pmc">chest</journal-id><journal-id journal-id-type="publisher-id">Chest</journal-id><journal-title-group><journal-title>Chest</journal-title></journal-title-group><issn pub-type="ppub">0012-3692</issn><issn pub-type="epub">1931-3543</issn><publisher><publisher-name>American College of Chest Physicians</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24626819</article-id><article-id pub-id-type="pmc">4122276</article-id><article-id pub-id-type="publisher-id">chest.13-1432</article-id><article-id pub-id-type="doi">10.1378/chest.13-1432</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Signs and Symptoms of Chest Diseases</subject></subj-group></subj-group></article-categories><title-group><article-title>Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children</article-title><alt-title alt-title-type="short">Omega-3 Fatty Acid Supplementation During Pregnancy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Escamilla-Nuñez</surname><given-names>María Consuelo</given-names></name><degrees>MSc</degrees></contrib><contrib contrib-type="author"><name><surname>Barraza-Villarreal</surname><given-names>Albino</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Hernández-Cadena</surname><given-names>Leticia</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Navarro-Olivos</surname><given-names>Efraín</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Sly</surname><given-names>Peter D.</given-names></name><degrees>MBBS, MD, DSc</degrees></contrib><contrib contrib-type="author"><name><surname>Romieu</surname><given-names>Isabelle</given-names></name><degrees>MD, MPH, ScD</degrees></contrib><aff id="aff1">From the Instituto Nacional de Salud Pública (Ms Escamilla-Nuñez and Drs Barraza-Villarreal, Hernández-Cadena, Navarro-Olivos, and Romieu), Cuernavaca, Morelos, Mexico; the World Health Organization Collaborating Centre for Research and Children’s Environmental Health (Dr Sly), Curtin University of Technology and Centre for Child of Western Australia, Perth, WA, Australia; and the International Agency for Research on Cancer (Dr Romieu), Lyon, France.</aff></contrib-group><author-notes><corresp id="cor1"><bold>CORRESPONDENCE TO:</bold> Albino Barraza-Villarreal, PhD, Instituto Nacional de Salud Publica, Av. Universidad # 655, Col. Santa María Ahuacatitlán, C. P. 62100, Cuernavaca, Morelos, México; e-mail: <email>abarraza@correo.insp.mx</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2015</year></pub-date><pmc-comment> PMC Release delay is 12 months and 0 days and was based on the
<volume>146</volume><issue>2</issue><fpage>373</fpage><lpage>382</lpage><history><date date-type="received"><day>20</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 AMERICAN COLLEGE OF CHEST PHYSICIANS</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="chest_146_2_373.pdf"></self-uri><abstract><sec><title>BACKGROUND:</title><p>Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.</p></sec><sec><title>METHODS:</title><p>We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18-35 years of age) to receive 400 mg/d of algal docosahexaenoic acid (DHA) or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months were available for 869 mother-child pairs. Questionnaires were administered, and maternal blood samples were obtained at baseline. Maternal atopy was based on specific IgE levels. During follow-up, information on infants’ respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12, and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.</p></sec><sec><title>RESULTS:</title><p>Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion (0.78; 95% CI, 0.60-1.02) and fever with phlegm and nasal discharge or nasal congestion (0.53; 95% CI, 0.29-0.99), adjusting for potential confounders.</p></sec><sec><title>CONCLUSIONS:</title><p>Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopy.</p></sec><sec><title>TRIAL REGISTRY:</title><p><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link>; No.: NCT00646360; URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link></p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |